Scorpion Therapeutics

Scorpion Therapeutics is a clinical-stage biotechnology company based in Boston, Massachusetts, founded in 2020. The company is dedicated to advancing precision oncology by developing next-generation small molecule drugs that target the molecular drivers of cancer. Its proprietary platform integrates expertise in cancer biology, medicinal chemistry, and computational data sciences to create highly selective compounds aimed at improving patient outcomes. The company's lead program, STX-478, is a PI3Kα kinase inhibitor currently being evaluated in clinical trials for breast cancer and other advanced solid tumors. Scorpion Therapeutics focuses on developing targeted small-molecule drugs for oncology, leveraging innovative technologies in target discovery and medicinal chemistry. With a strong leadership team and significant investment, including a recent $150 million Series C funding round, Scorpion is committed to expanding the reach of precision medicine to benefit more cancer patients.

Research Boston, United States ~16 employees Private · Series C

Work at Scorpion Therapeutics in HR or recruiting? Claim this page

Employees
16
0% in the 3 months to Sep 2026
Revenue / employee
$20K
Revenue ~$320K
Total funding
$445M
Last round Series C, Jul 2024
12-month attrition
78.8%
Tech: 73.5%
H1B sponsor
NA

Headcount trend

Scorpion Therapeutics went from 132 employees in Oct 2024 to 16 in Sep 2026.

Funding rounds

Total funding$445M
Funding rounds4
Investors23

Org structure

Headcount by department

Other10
Operations3
Engineering2
Marketing1

Scorpion Therapeutics FAQ

How many employees does Scorpion Therapeutics have?

Scorpion Therapeutics has about 16 employees, unchanged over the 3 months to Sep 2026.

What is Scorpion Therapeutics's revenue per employee?

Scorpion Therapeutics makes about $20K in revenue per employee, based on $320K annual revenue and 16 employees.

How much funding has Scorpion Therapeutics raised?

Scorpion Therapeutics has raised $444.68M in total funding; its latest round was Series C in Jul 2024.

Data from Company Prospectus, DOL LCA disclosures, WARN notices and 6figr salary profiles.